BPC-157: A Research Overview

Introduction

BPC-157 (Body Protection Compound-157) is a stable synthetic pentadecapeptide derived from a partial sequence of a protein originally isolated from human gastric juice. It is classified within the research literature as a stable gastric pentadecapeptide and has been investigated across a broad range of animal models covering gastrointestinal, musculoskeletal, neurological, and vascular contexts. This article is an educational reference summarizing its chemical identity, pharmacological classification, and regulatory status based on peer-reviewed publications.

Background

Research interest in BPC-157 originates from work conducted beginning in the early 1990s at the University of Zagreb, Croatia, under the direction of Predrag Sikirić and colleagues. The foundational 1993 publication in the Journal of Physiology, Paris introduced the molecule as a novel gastric juice peptide and described the overarching "stomach-stress-organoprotection" hypothesis, proposing that gastric-derived peptides mediate systemic protective responses [1]. Subsequent decades of preclinical investigation in the Sikirić laboratory — and, progressively, in independent research groups — extended the scope of inquiry to musculoskeletal tissue, the central nervous system, and the cardiovascular system.

A 2025 literature and patent review published in Pharmaceuticals by Józwiak and colleagues catalogued the breadth of the BPC-157 research corpus, identifying multiple pharmacological interaction networks investigated in cell culture and animal models [2]. The review characterized the compound's pleiotropic profile — a pattern in which a single agent is reported to interact with multiple distinct signaling pathways — as a central feature of the published literature, and noted that clinical investigation in humans is ongoing as the field progresses from preclinical characterization toward translational research.

Chemistry and Structure

BPC-157 is a 15-amino acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its molecular weight is approximately 1,419 daltons. The sequence is described in the literature as having no meaningful homology to other characterized mammalian peptides of equivalent length [1].

A structurally notable feature of the molecule is its high proline content: four of the 15 residues are proline, including a consecutive triple-proline stretch (Pro-Pro-Pro) near the N-terminus. Proline residues confer conformational rigidity and resistance to cleavage by many endopeptidases, which is consistent with the repeatedly cited observation that BPC-157 retains stability in gastric acid — an unusual property among peptides that typically undergo rapid enzymatic degradation under acidic conditions [1,2].

The synthetic form of BPC-157 used in research is chemically identical to the partial gastric sequence and is produced via solid-phase peptide synthesis. Pharmacokinetic studies in rats and dogs, published in Frontiers in Pharmacology in 2022, characterized the molecule's distribution, metabolism, and excretion profile, reporting metabolism into smaller peptide fragments and individual amino acids following parenteral administration [3].

Pharmacological Classification

In the published literature, BPC-157 is classified variously as a cytoprotective peptide, a stable gastric pentadecapeptide, and — in the context of early clinical development — an antiulcer agent. These designations reflect the historical origins of the research program in gastroenterology and the initial framing of the molecule as a candidate for inflammatory bowel disease investigation.

The pharmacological profile described in the research literature is multisystem. Published investigations have examined interactions with the nitric oxide (NO) signaling axis, the vascular endothelial growth factor (VEGF) pathway, the dopaminergic and serotonergic systems, growth hormone receptor expression in fibroblasts, and focal adhesion kinase (FAK)-mediated cell migration pathways [2,4,5]. Each of these represents a distinct signaling network characterized primarily in preclinical models. The molecular mechanisms underlying these interactions are covered in detail in the BPC-157 mechanism of action article.

A 2025 narrative review in Current Reviews in Musculoskeletal Medicine by Lulofs and colleagues described BPC-157 as activating "several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis," based on observations in preclinical models, and identified translational clinical investigation as an important next step in the research program [6].

Discovery History

The discovery of BPC-157 is attributed to the research group led by Predrag Sikirić at the University of Zagreb. The group's 1993 paper in Journal of Physiology, Paris described a protein originally designated BPC (Body Protection Compound), isolated and characterized from human gastric juice, and identified partial peptide sequences derived from it — among which BPC-157 emerged as a subject of sustained experimental focus [1].

The name reflects this origin: "Body Protection Compound" denotes the parent protein source, and "157" is a sequence identifier from the original characterization work. Subsequent publications established the 15-amino acid sequence as the molecule of interest, standardized synthesis procedures, and began the systematic preclinical characterization that has continued across more than three decades.

The compound attracted broader scientific attention during the 2010s as independent research groups published findings using BPC-157 in diverse animal model systems, and as interest in peptide science expanded in both academic and commercial contexts. Other regenerative peptides investigated across similar musculoskeletal and vascular model systems during this period include TB-500, another compound in the healing and regenerative research cluster. A 2025 systematic review published in HSS Journal by Vasireddi and colleagues surveyed the growing body of orthopaedic and sports medicine research on BPC-157, reflecting the broadening scope of preclinical and translational inquiry [8].

Regulatory Status

Research-grade BPC-157 from SpartaLabs is verified by third-party testing and accompanied by a certificate of analysis for each batch. BPC-157's regulatory trajectory reflects the natural progression of a research-stage compound through the scientific pipeline. During the early 2000s and 2010s, the Croatian pharmaceutical company Pliva conducted early-phase clinical investigations of BPC-157 formulations (designated PL-10, PLD-116, and PL14736) in small human studies involving inflammatory bowel disease and wound healing. These studies, referenced in subsequent preclinical publications, established a preliminary human safety profile for the compound [7].

As of the preparation of this article, BPC-157 does not hold marketing authorization from the FDA, the EMA, or equivalent regulatory bodies for any therapeutic indication. The 2025 review by Józwiak and colleagues noted that comprehensive clinical studies confirming health benefits in humans remained an active area of investigation [2]. BPC-157 is classified as a research-use-only (RUO) compound in the United States and is produced for scientific research applications.

References

1. Sikirić P, Petek M, Rucman R, Seiwerth S, Grabarević Z, Rotkvić I, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313–327. PMID: 8298609. https://pubmed.ncbi.nlm.nih.gov/8298609/

2. Józwiak P, Lipiec K, Maleszka A, Krześlak A. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals. 2025;18(2):185. PMID: 40005999. DOI: 10.3390/ph18020185. https://pubmed.ncbi.nlm.nih.gov/40005999/

3. He Y, Chang R, Han B, Shi C, Li Y, Wang H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1086885. PMC9794587. https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/

4. Hsieh MJ, Lee CH, Chueh HY, Ho TY, Lin CY, Chen KB, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. PMID: 33051481. DOI: 10.1038/s41598-020-74064-0. https://pubmed.ncbi.nlm.nih.gov/33051481/

5. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–77. PMC6271067. DOI: 10.3390/molecules191119066. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/

6. Lulofs R, Spaans M, Kokshoorn NE. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025. PMID: 40789979. https://pubmed.ncbi.nlm.nih.gov/40789979/

7. Sikirić P, Seiwerth S, Grabarević Z, Rucman R, Petek M, Jagić V, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. J Pharmacol Sci. 2007;104(1):7–17. PMID: 17713731. https://pubmed.ncbi.nlm.nih.gov/17713731/

8. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PMID: 40756949. DOI: 10.1177/15563316251355551. https://pubmed.ncbi.nlm.nih.gov/40756949/